Sakar Healthcare Ltd
Sakar Healthcare Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #9 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
3 of 5 strong
The short version
Oncology revenue expected to double from INR100 crores in FY26 to INR200 crores in FY27, and triple to around INR280-300 crores in FY28. Oncology business expected to nearly double revenue from INR100 crores to INR200 crores in FY27 and triple to INR280-300 crores in FY28.
From Sakar Healthcare Ltd's Q1 FY27 earnings-call transcript · updated 3 Sept 2026.
Revenue & Sales Performance
- Oncology revenue expected to double from INR100 crores in FY26 to INR200 crores in FY27, and triple to around INR280-300 crores in FY28.
- Total oncology revenue potential estimated between INR800 crores to INR1,000 crores within 3-4 years.
- Export business contribution expected to rise to about 30% of oncology sales by FY27, driven by marketing authorizations and site variations.
- Domestic CMO business for oncology targeted to double from approximately INR35 crores in FY26 to about INR70 crores in FY27.
- Non-oncology (CDMO and API) business expected to grow steadily at 7-8% CAGR in line with generic market trends.
2 more points from Sakar Healthcare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sakar Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No further capex or capital investment is planned for the next few years as the current facility supports ongoing and upcoming product development.
- The existing setup is sufficient to commercialize 6-7 additional molecules coming off-patent in the next couple of years without requiring expansion.
- Focus remains on expanding dossier submissions, regulatory approvals, and commercialization within the current infrastructure.
2 more points from Sakar Healthcare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sakar Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Sakar Healthcare currently has over 250 dossiers registered or in pipeline for export markets, indicating a strong orderbook for oncology products.
- 178 dossiers have already been submitted to regulatory agencies worldwide, with 16 marketing authorizations (MAs) approved so far.
- Another 50-plus dossiers are expected to be submitted within the next 1-2 quarters, with an addition of around 25-30 dossiers every quarter going forward.
- The company has completed more than 50-60 export agreements/contracts overseas and 15 contracts in the domestic market.
2 more points from Sakar Healthcare Ltd's call on order book
Create a free account to keep reading this call
Sakar Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹87 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sakar Healthcare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sakar Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sakar Healthcare Ltd Q1 FY27 results?
Oncology revenue expected to double from INR100 crores in FY26 to INR200 crores in FY27, and triple to around INR280-300 crores in FY28. Oncology business expected to nearly double revenue from INR100 crores to INR200 crores in FY27 and triple to INR280-300 crores in FY28.
What is Sakar Healthcare Ltd share price analysis?
Sakar Healthcare Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 54.0 with a market cap of ₹1,948 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sakar Healthcare Ltd planning capital expenditure?
No further capex or capital investment is planned for the next few years as the current facility supports ongoing and upcoming product development.
Keep Sakar Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.